Cybin Inc. (NYSE AMERICAN:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce the voting results for each of the matters presented at the Company’s annual and special meeting of shareholders held on October 12, 2023 (the “Meeting”). There were 66 shareholders represented in person or by proxy at the Meeting holding 91,903,025 common shares, representing 39.16% of Cybin’s total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting are set out below:
1. Acquisition Resolution
The acquisition of Small Pharma Inc. (“Small Pharma”), by way of a proposed plan of arrangement under the Business Corporations Act (British Columbia), pursuant to the terms and subject to the conditions of the arrangement agreement between Cybin and Small Pharma, dated August 28, 2023, was approved. Voting results are set out below:
| Votes For | Votes Against |
| # | % | # | % |
| 43,199,295 | 99.410 | 256,200 | 0.590 |
2. Appointment of Auditor
Zeifmans LLP was appointed auditor of Cybin until the next annual meeting of shareholders at renumeration to be fixed by the directors of Cybin. Voting results are set out below:
| Votes For | Votes Withheld |
| # | % | # | % |
| 91,252,133 | 99.292 | 650,891 | 0.708 |
The special resolution to set the number of directors of Cybin at six was approved by at least two-thirds of the votes casts by the shareholders who voted in respect of the resolution present or represented by proxy at the Meeting. Voting results are set out below:
| Votes For | Votes Against |
| # | % | # | % |
| 90,712,567 | 98.705 | 1,190,458 | 1.295 |
Each of the nominees for election as director listed in Cybin’s management information circular dated September 13, 2023 were elected as directors of Cybin for the ensuing year or until their successors are elected or appointed. Voting results are set out below:
| | Votes For | Votes Withheld |
| | # | % | # | % |
| Theresa Firestone | 42,976,922 | 98.899 | 478,573 | 1.101 |
| Grant Froese | 43,022,128 | 99.003 | 433,368 | 0.997 |
| Paul Glavine | 43,012,466 | 98.980 | 443,030 | 1.020 |
| Eric Hoskins | 42,906,846 | 98.737 | 548,649 | 1.263 |
| Mark Lawson | 42,971,117 | 98.885 | 484,379 | 1.115 |
| Eric So | 39,668,729 | 91.286 | 3,786,767 | 8.714 |
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions.
Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The Company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds.
Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.